Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1). $3.0M upfront license fee due within 30 days for late-stage rare disease candidate ASN-001.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $3.0M upfront license fee due within 30 days for late-stage rare disease candidate ASN-001
- Bioavailability bridging study required before planned NDA submission in 2H 2027
- FDA approval triggers $5.0M first-sale milestone plus up to $33.5M sales-based milestones
- Tiered royalties based on cumulative lifetime sales: 10%, 13%, or 15%
- Agreement adds development and launch opportunity, but approval and milestone payments remain contingent on clinical and commercial success
Item EX-99.1 · Exhibit EX-99.1
- U.S. rights license for ASN-001 expands Eton’s infantile hemangioma franchise beyond HEMANGEOL’s systemic-treatment segment
- Phase II/III results: week-24 elimination or near-elimination rates of 56% BID and 42% TID versus 15% placebo
- 168-patient trial supports late-stage development, but Eton still requires a bioavailability bridging study
- NDA targeted for 2H 2027, with potential approval and launch in 2028
- Estimated 20,000–30,000 annual candidates and patent protection through 2044 support potential portfolio-leading revenue opportunity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.